View More Recent Stories
-
Acadia Pharma (ACAD) Tops Q2 EPS by 2c, provides guidance
-
Acadia Pharma (ACAD): Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating DAYBUE in Patients with Rett Syndrome Published
-
TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
BMO Capital Starts Acadia Pharmaceuticals (ACAD) at Outperform
-
Acadia Pharma (ACAD) Presents DAYBUE Real-World Evidence and Additional Data in Rett Syndrome
